Summit Therapeutics Inc [SMMT] stock prices are up 2.45% to $20.89 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SMMT shares have gain 12.01% over the last week, with a monthly amount glided 6.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on November 04, 2024, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $32. Previously, Citigroup downgraded its rating to Neutral on September 27, 2024, and elevated its price target to $23. On August 12, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $16 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $7 on May 07, 2024. Stifel initiated its recommendation with a Buy and recommended $8 as its price target on March 26, 2024. Janney downgraded its rating to Neutral for this stock on June 28, 2018. In a note dated May 02, 2018, Janney initiated an Buy rating.
The stock price of Summit Therapeutics Inc [SMMT] has been fluctuating between $1.64 and $33.89 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $20.89 at the most recent close of the market. An investor can expect a potential return of 67.54% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
Gross Profit Margin for this corporation currently stands at 3.86% with Operating Profit Margin at 773.39%, Pretax Profit Margin comes in at 837.61%, and Net Profit Margin reading is 836.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -1.04 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.61 points at the first support level, and at 18.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.56, and for the 2nd resistance point, it is at 22.24.
Ratios To Look Out For
It’s worth pointing out that Summit Therapeutics Inc [NASDAQ:SMMT]’s Current Ratio is 8.31. Also, the Quick Ratio is 8.31, while the Cash Ratio stands at 1.59.
Transactions by insiders
Recent insider trading involved Zanganeh Mahkam, Chief Executive Officer, that happened on Mar 27 ’24 when 54321.0 shares were purchased. Chief Executive Officer, Zanganeh Mahkam completed a deal on Mar 26 ’24 to buy 30000.0 shares. Meanwhile, Chief Executive Officer Zanganeh Mahkam bought 26000.0 shares on Mar 27 ’24.
